Login Get Started
Browse
Shares
Healthcare
Pharmaceuticals
Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc logo

VRCA - Verrica Pharmaceuticals Inc Share News

$13.68 0.3  2.5%

Last Trade - 05/03/21

Sector
Healthcare
RiskRating
Adventurous
Size
Small Cap
Style
Style Neutral
Market Cap £255.6m
Enterprise Value £229.0m
Revenue £n/a
Position in Universe 3821st / 6651
Quality
Value
Momentum
StockRank™
StockReport™
Tools
Compare with... Run through checklist
Accounts
Balance sheet Income statement Cashflow statement Dividend summary
Charts News Discussions VRCA Dividends
All News
All News Reuters News Company Announcements
BRIEF-Verrica Reports Quarterly Loss Per Share Of $0.52
Thu 12:39pm News
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results
Thu 12:30pm News
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
Wed 12:30pm News
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
23rd Feb News
BRIEF-Verrica Announces FDA Filing Acceptance Of Resubmitted NDA For VP-102 For Treatment Of Molluscum Contagiosum
17th Feb News
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
17th Feb News
BRIEF-Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating Safety And Efficacy Of VP-102 In Molluscum And External Genital Warts At 2021 Winter Clinical Dermatology Conference
19th Jan News
Verrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
19th Jan News
BUZZ-Verrica Pharma: Wainwright sees FDA approval for skin disease drug; hikes PT
24th Dec '20 News
U.S. RESEARCH ROUNDUP-Gentherm, HMS Holdings, Paychex
24th Dec '20 News
BRIEF-Verrica Pharmaceuticals Announces Resubmission Of New Drug Application For VP-102 For The Treatment Of Molluscum Contagiosum
23rd Dec '20 News
Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
23rd Dec '20 News
BRIEF-Verrica Pharma Announces Receipt Of Final FDA Minutes Following Type A Meeting Regarding Resubmission Of The NDA For VP-102 In Molluscum
17th Nov '20 News
Verrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum
17th Nov '20 News
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
12th Nov '20 News
BRIEF-Verrica Pharmaceuticals Announces Positive Topline Results In Phase 2 Clinical Study Of VP-102 In Patients With External Genital Warts
10th Nov '20 News
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1)
10th Nov '20 News
BRIEF-Verrica Pharmaceuticals Reports Qtrly Net Loss Per Share Of $0.42
9th Nov '20 News
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results
9th Nov '20 News
BRIEF-Jama Dermatology Publishes Results From Verrica's Two Pivotal Phase III Camp Trials
23rd Sep '20 News
© Stockopedia 2021, Refinitiv, Share Data Services.
Youtube Instagram RSS
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.